China Medical Systems In-Licenses Respiratory Distress Drug from Faron

China Medical Systems, headquartered in Shenzhen, in-licensed greater China rights to Traumakine®, a treatment for moderate to severe acute respiratory distress syndrome (ARDS) from Faron Pharma, a Finnish virtual biopharma. At the same time, A&B Ltd., a company owned by Dr. Kong Lam, the CEO of China Medical Systems, made a $5.5 million investment in Faron. A&B will also underwrite the costs of regulatory approval in China. Details of the arrangement between A&B and China Medical Systems were not disclosed.  More details.... Stock Symbol: (HK: 867) Share this with colleagues: // //